Data presented at American College of Cardiology (ACC) 2020
Due to COVID-19 concerns, many medical congresses are being presented virtually. Virtual congress materials from ACC can be accessed at https://accscientificsession.acc.org/
- The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial.
- Effects of canagliflozin on cardiovascular, renal and safety outcomes by baseline loop diuretic use: data from the CREDENCE trial.
- Canagliflozin (CANA) reduces cardiovascular (CV) and renal events independent of baseline heart failure (HF): a CREDENCE secondary analysis.
- Effects of canagliflozin on stroke in the CREDENCE trial.